The antitumor activity of exogenous and endogenous canstatin on colorectal cancer cells.
Colorectal cancer is the third most common malignancy and the third-leading cause of cancer-related deaths worldwide. In the last several years, recombinant DNA technology has made cancer gene therapy feasible in the clinic. In our studies, we used both exogenous and endogenous canstatin, a type IV collagen genetically distinct product. We detected the effects of canstatin on colorectal cancer cells HCT-15 and HCT-116. DAPI staining, FCM and migration analyse were used to detect the apoptotic cells, cell cycle and mobility. As shown in the results, the apoptotic cell numbers (p<0.05) and G1 arrest cell numbers (p<0.05) were higher than in the non- treatment case. The mobility of the cells was also decreased obviously (p<0.05). Simultaneously, combination effects of exogenous and endogenous canstatin were identified.
Department of Surgical Oncology, First Affiliated Hospital of China Medical University, Shenyang, China.
Ya-Nan
YN
Xing
Hong-Wei
HW
Liang
Li
L
Zhao
Hui-Mian
HM
Xu
D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D024141:Collagen Type IV / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology*; D015179:Colorectal Neoplasms / Q000235:genetics* / Q000378:metabolism*; D059585:G1 Phase Cell Cycle Checkpoints / Q000187:drug effects*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007211:Indoles; D010446:Peptide Fragments / Q000235:genetics / Q000494:pharmacology; D011994:Recombinant Proteins / Q000235:genetics / Q000494:pharmacology
C502625:COL4A2 protein, human; D024141:Collagen Type IV; D007211:Indoles; D010446:Peptide Fragments; D011994:Recombinant Proteins; C007293:DAPI